Icosavax Inc (DELISTED) (ICVX:DL)
15.31
0.00 (0.00%)
USD |
NASDAQ |
Feb 29, 16:00
Icosavax Research and Development Expense (TTM): 70.04M for Sept. 30, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2023 | 70.04M |
| June 30, 2023 | 68.86M |
| March 31, 2023 | 64.85M |
| December 31, 2022 | 65.41M |
| September 30, 2022 | 63.28M |
| June 30, 2022 | 58.68M |
| Date | Value |
|---|---|
| March 31, 2022 | 51.14M |
| December 31, 2021 | 38.78M |
| September 30, 2021 | 30.04M |
| June 30, 2021 | 23.91M |
| March 31, 2021 | 20.30M |
| December 31, 2020 | 17.67M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
17.67M
Minimum
Dec 2020
70.04M
Maximum
Sep 2023
47.75M
Average
54.91M
Median
Research and Development Expense (TTM) Benchmarks
| Karuna Therapeutics Inc (DELISTED) | 364.10M |
| Immunogen Inc (DELISTED) | 207.75M |
| AbbVie Inc | 7.322B |
| Assure Holdings Corp | -- |
| Harpoon Therapeutics Inc (DELISTED) | 58.63M |